Pedro Oliveira, MD
Neurology · Baton Rouge, LANPI 1982993655
Payments from drug & device makers
Across 300 payments — averaging $12.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$347
- MDD US Operations, LLC$293
- Lundbeck LLC$268
- Biohaven Pharmaceuticals, Inc.$171
- Argenx US, Inc.$160
- plus $923 from 18 others
What the payments were for
- Food & beverage$3,69098%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 177 | $1,589 |
| Teva Pharmaceuticals USA, Inc. | 21 | $347 |
| MDD US Operations, LLC | 19 | $293 |
| Lundbeck LLC | 16 | $268 |
| Biohaven Pharmaceuticals, Inc. | 19 | $171 |
| Argenx US, Inc. | 8 | $160 |
| Lilly USA, LLC | 8 | $141 |
| Eisai Inc. | 1 | $122 |
| Pfizer | 6 | $98 |
| Jazz Pharmaceuticals Inc. | 1 | $97 |
| Globus Medical | 1 | $75 |
| Novartis | 4 | $69 |
| Johnson & Johnson(2 entities) | 4 | $69 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| AstraZeneca | 1 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| CSL Behring | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$122
How this compares
$3,751 in reported general payments places this provider in the 50th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 23 | $210,593 |
| AustedoDeutetrabenazine | 13 | $190,356 |
| Aimovig AutoinjectorErenumab-Aooe | 83 | $79,895 |
| CopaxoneGlatiramer Acetate | 13 | $75,816 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $47,016 |
| RytaryCarbidopa/Levodopa | 36 | $40,507 |
| Nurtec OdtRimegepant Sulfate | 23 | $35,980 |
| LamictalLamotrigine | 11 | $25,007 |
| RexultiBrexpiprazole | 12 | $17,069 |
| Memantine Hcl | 671 | $15,567 |
| TopamaxTopiramate | 11 | $11,510 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $11,313 |
| UbrelvyUbrogepant | 11 | $10,823 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 88 | $6,720 |
| RivastigmineRivastigmine Tartrate | 150 | $5,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $347 | $266,17226 claims |
| PfizerOctagam, Nurtec Odt | $98 | $246,57346 claims |
| CSL BehringPrivigen | $11 | $47,01611 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $29 | $44,918105 claims |
| AbbVieNamzaric, Ubrelvy | $1,589 | $22,13623 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $27 | $17,06912 claims |
| Lundbeck LLCOnfi | $268 | $4,80711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 225 neurology providers in Louisiana.
Other neurology in Baton Rouge
- Jon OlsonBaton Rouge$1.7M
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- Benjamin KidderBaton Rouge$35K
- Joseph AcostaBaton Rouge$33K
- William GladneyBaton Rouge$19K
- David GlossBaton Rouge$15K
- Ariel Antezana AntezanaAlexandria$2.5M
- Bridget BagertNew Orleans$1.4M
- Carol RedillasChalmette$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.